98
Participants
Start Date
March 31, 2002
Primary Completion Date
October 31, 2003
Study Completion Date
October 31, 2003
darbepoetin alfa
starting dose determined by calculating a subject's total dose in the month preceding enrollment. Administered QM for 25 weeks. Change made as necessary to maintain a hemoglobin concentration within the target range os 10.0 - 12.0 g.dL
Lead Sponsor
Amgen
INDUSTRY